Clinical Scorecard: Revisiting Osteoclast-Osteoblast Interactions: A Comprehensive Framework for Understanding Their Communication and Implications for Therapy

At a Glance

Key Highlights

• Osteoclasts originate from multiple embryonic hematopoietic waves creating lifelong heterogeneity influencing coupling with osteoblasts.
• Pre-osteoclasts act as dominant coupling effectors coordinating osteoblast recruitment and vascularization independently of bone resorption.
• Core signaling cascades (BMP, sphingolipid/sclerostin, WNT) converge to form a robust, tunable osteoclast–osteoblast communication network.

Guideline-Based Recommendations

Diagnosis

• Consider osteoclast lineage heterogeneity and coupling capacity in evaluating bone remodeling disorders.
• Use lineage-tracing and molecular profiling tools where available to assess osteoclast developmental origin.

Management

• Therapeutic strategies should aim to expand the coupling-competent pre-osteoclast pool rather than broadly suppress or stimulate remodeling.
• Target signaling pathways involved in osteoclast–osteoblast communication (e.g., BMP, WNT, sphingolipid pathways) for disease-modifying effects.

Monitoring & Follow-up

• Monitor bone remodeling dynamics with attention to coupling efficiency between resorption and formation phases.
• Assess biomarkers related to pre-osteoclast secretome factors (e.g., sphingosine-1-phosphate, PDGF-BB) to evaluate therapeutic impact.

Risks

• Broad suppression of osteoclast activity may disrupt endogenous coupling networks, impairing bone formation and skeletal homeostasis.
• Incomplete understanding of osteoclast heterogeneity may lead to suboptimal therapeutic outcomes.

Patient & Prescribing Data

Patients with osteoporosis and other bone remodeling disorders

Current therapies often fail to modify disease due to disruption of osteoclast–osteoblast communication; next-generation therapies should preserve or enhance coupling mechanisms, particularly by targeting pre-osteoclast populations.

Clinical Best Practices

• Incorporate knowledge of osteoclast developmental origin and heterogeneity into clinical assessment and treatment planning.
• Focus on therapies that maintain or enhance the multi-layered communication network between osteoclasts and osteoblasts.
• Avoid indiscriminate suppression of osteoclast activity to prevent uncoupling of bone resorption and formation.
• Consider emerging coupling factors (e.g., cardiotrophin-1, SLIT3, C3a, CTHRC1) as potential therapeutic targets or biomarkers.

References

• Bone remodeling and osteoclast-osteoblast communication overview
• Lineage tracing of osteoclast origins
• Pre-osteoclast secretome and coupling factors